BD-tau has demonstrated to be a promising marker of neurodegeneration in AD17 and a severity indicator in traumatic brain injury.18 A recent study have demonstrated BD-tau to be a potential marker of functional outcome after AIS,19 however validation across multiple cohorts is still pending. This evidence concerns the gene MAPT and androgen insensitivity syndrome.